GlassScriptPhysician profile
Katherine Flanagan
NPI 1104092675
$3,933.03
in general payments reported to CMS, 2019-2025
31 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $378 · 2021: $940 · 2022: $672 · 2023: $497 · 2024: $506 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,081.03 | 2019-2025 | |
| Janssen Biotech, INC. | $469.66 | 2019-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $348.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $217.24 | 2019-2024 | Dupixent |
| Leo Pharma INC. | $173.87 | 2019-2024 | Adbry |
| Pfizer INC. | $171.98 | 2019-2023 | |
| Merz North America, INC. | $136.26 | 2022-2024 | Xeomin |
| Genzyme Corporation | $130.65 | 2020-2024 | |
| Allergan, INC. | $124.98 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $115.17 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $102.45 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $90.86 | 2022-2024 | Sotyktu |
| Genentech USA, INC. | $89.75 | 2019-2021 | |
| Lilly USA, LLC | $86.49 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $80.27 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $64.00 | 2023-2024 | |
| Ucb, INC. | $63.12 | 2019-2024 | Bimzelx |
| Aclaris Therapeutics, INC. | $52.53 | 2019 | |
| Galderma Laboratories, L.P. | $50.64 | 2019-2024 | |
| Amgen INC. | $48.69 | 2021-2025 | Otezla, Otezla |
| Dusa Pharmaceuticals, INC. | $46.79 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.51 | 2019 | |
| Dermavant Sciences, INC. | $26.21 | 2023 | Vtama |
| Almirall LLC | $24.86 | 2019 | |
| Verrica Pharmaceuticals INC. | $24.75 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $22.21 | 2021 | |
| Biofrontera INC. | $19.55 | 2021 | |
| Dermira, INC. | $16.24 | 2020 | |
| Fresenius Kabi USA, LLC | $14.91 | 2023 | |
| Organon LLC | $5.82 | 2025 | |
| Prugen, INC. Pharmaceuticals | $5.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Flanagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.